MiraLAX Disease Interactions
There are 3 disease interactions with MiraLAX (polyethylene glycol 3350).
Laxatives (applies to MiraLAX) inflammatory bowel disease
Major Potential Hazard, Moderate plausibility.
The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.
Laxatives (applies to MiraLAX) intestinal obstruction disorders
Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction
The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.
PEG solutions (applies to MiraLAX) GI obstruction/perforation
Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction, Gastrointestinal Perforation, Ulcerative Colitis
The use of polyethylene glycol (PEG) solutions is contraindicated in patients with gastrointestinal obstruction, perforation, or toxic megacolon. If gastrointestinal obstruction or perforation is suspected, appropriate studies should be performed prior to administration of these agents. Use with caution in patients with severe active ulcerative colitis. Increased activity of the gut caused by these agents could worsen these conditions.
Switch to professional interaction data
MiraLAX drug interactions
There are 222 drug interactions with MiraLAX (polyethylene glycol 3350).
Report options
More about MiraLAX (polyethylene glycol 3350)
- MiraLAX consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (263)
- Side effects
- Dosage information
- During pregnancy
- Support group
- Drug class: laxatives
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Linzess
Linzess (linaclotide) is used to treat chronic idiopathic constipation, irritable bowel syndrome ...
Amitiza
Amitiza (lubiprostone) is used to treat chronic constipation and irritable bowel syndrome with ...
Cosentyx
Cosentyx (secukinumab) is used to treat plaque psoriasis, psoriatic arthritis, ankylosing ...
Trulance
Trulance (plecanatide) is used to treat chronic idiopathic constipation (CIC) and irritable bowel ...
Ibsrela
Ibsrela (tenapanor) is used for the treatment of irritable bowel syndrome with constipation ...
GlycoLax
GlycoLax is used for bowel preparation, constipation, constipation, acute, irritable bowel ...
Xphozah
Xphozah (tenapanor) is a phosphate absorption inhibitor that is used lower serum phosphorus levels ...
ClearLax
ClearLax is used for bowel preparation, constipation, constipation, acute, irritable bowel ...
Tenapanor
Tenapanor is used for hyperphosphatemia of renal failure, irritable bowel syndrome with constipation
Plecanatide
Plecanatide is used for chronic idiopathic constipation, constipation, irritable bowel syndrome ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.